Importantly, EZH2-mediated SMAD3 methylation not only rendered cancer cells more vulnerable to TGFB1 and promoted cancer cell EMT and metastasis, but also showed a positive correlation with poor patient survival (Figure 8E). Here, SMAD3 is linked to cancer.